Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Receptor BioLogix Inc.

Division of Symphogen AS

Latest From Receptor BioLogix Inc.

The A-List: 2009's Trend-Shaping Series A Financings

New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. In biopharmaceuticals, corporate venture got in at the ground floor while device start-ups continued to see stronger support from smaller, regional investors than traditional VCs.
BioPharmaceutical Medical Device

Halozyme Therapeutics makes new appointment

Halozyme Therapeutics, a US biopharmaceutical company developing and commercialising products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, has named Dr Michael Shepard vice-president of discovery research. He has more than 25 years' experience in the biotechnology industry, having most recently been founder and president of Receptor BioLogix. At Genentech, Dr Shepard led the team that discovered the breast cancer drug Herceptin (trastuzumab). In 2007, he shared the Warren Alpert Prize from Harvard Medical School in recognition of the achievement.

Cancer Companies

Best of the Blog: IN VIVO February 2009

A roundup of our best February blog posts not covered elsewhere in the magazine includes Biotech's Winter and the March of the EarnOuts; Infant formula division Mead Johnson milks investors of $720 million in IPO; Dont Come Knockin' on my Door: Survey shows physicians restrict drug rep access.

The A-List: 2008's Trend Shaping Series A Financings

Despite a miserable economy, new company formation continues apace. In biotech, recapitalizations and structured deals featured prominently; in diagnostics, interest remains strong even if rounds in 2008 were down from last year's highs; in devices, small and regional VCs have filled the void left by brand-name investors.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Symphogen AS
  • Senior Management
  • Janet I Swearson, CFO
  • Contact Info
  • Receptor BioLogix Inc.
    Phone: (650) 856-4600
    3350 West Bayshore Rd.
    Ste. 150
    Palo Alto, CA 94303